Brief: Genprex Announces U.S. Patent For Reqorsa Immunogene Therapy In Combination With Immune Checkpoint Inhibitors To Treat Cancers
16/08/2022 12:41
Aug 16 (Reuters) - Genprex Inc GNPX.O :
* GENPREX ANNOUNCES U.S. PATENT FOR REQORSA™ IMMUNOGENE
THERAPY IN
COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS TO TREAT CANCERS
Source text for Eikon: ID:nPn9sJVL7a
Further company coverage: GNPX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Genprex
See all newsBrief: Genprex Announces Collaboration With Roche Diagnostics For Biomarker Assay Validation Studies
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy